98%
921
2 minutes
20
Generally, weak muscle power is associated with high mortality. We aimed to evaluate the unknown association between % predicted value forced vital capacity (FVC% predicted) and mortality in asymptomatic older people, and the impact of muscle power on this association. We analyzed the Tsurugaya cohort that enrolled Japanese people aged ≥70 for 15 years with Cox proportional hazards model. Exposure variables were FVC% predicted and leg power. The outcome was all-cause mortality. The subjects were divided into quartiles by FVC% predicted or leg power, or into two groups by 80% for FVC% predicted or by the strongest 25% for leg power. Across 985 subjects, 262 died. The males with lower FVC% predicted exhibited higher mortality risks. The hazard ratio (HR) was 2.03 (95% CI 1.30−3.18) at the lowest relative to the highest groups. The addition of leg power reduced the HR to 1.78 (95% CI 1.12−2.80). In females, FVC% predicted under 80% was a risk factor and the HR was 1.67 (95% CI 1.05−2.64) without the effect of leg power. In FVC% predicted <80% males HRs were 2.44 (95% CI 1.48−4.02) in weak and 1.38 (95% CI 0.52−3.64) in strong leg power males, relative to ≥80% and strong leg power males. Low FVC% predicted was associated with high mortality with potential unfavorable effects of weak leg power in males.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505108 | PMC |
http://dx.doi.org/10.3390/jcm11185264 | DOI Listing |
Pulm Ther
September 2025
Department of Pulmonary Function Test, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Introduction: Preserved ratio impaired spirometry (PRISm) is an important phenotype of pulmonary function in clinical and public health practice. It is possible for some patients to have chronic obstructive pulmonary disease (COPD) at an early stage. At present there is little research on the association of PRISm with type 2 (T2) inflammation biomarkers.
View Article and Find Full Text PDFRheumatology (Oxford)
September 2025
Department of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Objectives: This study aimed to establish a risk prediction model for the relapse of anti-synthetase syndrome-associated interstitial lung disease (ASyS-ILD).
Methods: Patients diagnosed with ASyS-ILD and treated with prednisolone and calcineurin inhibitors as remission induction therapy were enrolled in the Japanese multicentre MYKO cohort. We followed up on patients who experienced relapse of ASyS-ILD after remission induction therapy, and examined the risk factors for predicting relapse by comparing initial clinical and laboratory findings.
BMC Pulm Med
September 2025
Department of Medical Biochemistry, Faculty of Medicine, İstanbul Atlas University, 34403, Istanbul, Turkey.
Background: Chronic obstructive pulmonary disease (COPD) is a chronic and progressive condition that develops due to a genetic predisposition, with the dysfunction of antioxidants and anti-protease systems triggered by factors such as smoking. In this study, we aimed to determine the effects of smoking on serum 8-hydroxy-2' deoxyguanosine (8-OHdG) as a marker of oxidative DNA damage, malondialdehyde (MDA) to indicate lipid peroxidation, protein carbonyl (PCO) as a marker of protein damage, and paraoxonase (PON)1 levels as a measure of antioxidant activity involved in maintaining cellular redox balance in COPD patients.
Methods: We conducted a cross-sectional study involving 141 patients with COPD (70 smokers, 71 non-smokers) and 140 healthy controls (70 smokers, 70 non-smokers) recruited from the Acibadem Mehmet Ali Aydinlar University outpatient clinic.
J Korean Med Sci
September 2025
Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Background: Acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) has the most disastrous impact on prognosis as a major cause of morbidity and mortality. However, there is no proven treatment, and the occurrence of AE is unpredictable. This study aimed to develop a prediction model for AE in patients with IPF using the nationwide Korea IPF Cohort (KICO) registry.
View Article and Find Full Text PDFAm J Ind Med
September 2025
Centers for Disease Control and Prevention, Surveillance Branch, Respiratory Health Division, National Institute for Occupational Safety and Health, Morgantown, West Virginia, USA.
Background: Small airways disease is a risk factor for the development of obstructive lung disease and may be present among coal miners without obstructive ventilatory impairment. Our study estimated the prevalence of reduced spirometric mid-expiratory flow among coal miners without obstructive ventilatory impairment.
Methods: Data were from coal miners participating in the Coal Workers' Health Surveillance Program (CWHSP) during 2014-2022 with forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) meeting quality criteria and no missing spirometry parameter values.